齊翔騰達(002408.SZ)擬投資2億元設立化工銷售公司
格隆匯2月20日丨齊翔騰達(002408.SZ)公佈,公司擬使用自有資金2億元投資設立全資子公司。公司名稱暫定為淄博齊翔騰達化工銷售有限公司(以工商實際註冊為準),經營範圍包括採購母公司及所屬子公司所需原材料;銷售母公司及所屬子公司產品;進出口(以相關部門批准及工商登記為準)。
本次投資設立全資子公司,意在實行集中化的原料及產品購銷模式,降低原料採購風險,對化工板塊的產品實行統一銷售,進一步提高決策效率和資金利用率,實現對生產成本及利潤的精準控制。通過新設全資子公司,對採購、銷售環節集中管理,將進一步加強與供應鏈業務的協同效應,對公司的長遠發展和企業效益將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.